Ventricular Tachycardia (VT) is a cardiac arrhythmia characterized by a rapid and regular heartbeat originating in the heart's lower chambers, the ventricles. In VT, the heart beats at a significantly faster rate than normal, disrupting its regular rhythm. This condition poses serious health risks as it may lead to inadequate blood flow to the body and, in severe cases, progress to more life-threatening arrhythmias. Ventricular Tachycardia can occur in individuals with pre-existing heart conditions, such as coronary artery disease or structural heart abnormalities, but it can also manifest in those with otherwise healthy hearts. Prompt diagnosis and management are crucial to prevent complications and improve patient outcomes, often involving anti-arrhythmic medications, catheter ablation, or, in severe cases, implantable cardioverter-defibrillator (ICD) placement. Regular monitoring and collaboration between healthcare professionals play a vital role in effectively addressing Ventricular Tachycardia and ensuring the well-being of affected individuals.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India